Ajooni Biotech logo

Ajooni Biotech financials: balance sheet, profit and loss, cash flow

NSE: AJOONIFood ProductsSmall Cap

Ajooni Biotech Limited · Face value ₹2 · Listed Jan 2018 · Issue price ₹40
Last close ₹2.87down ₹0.06 (2.05%)

Share price at the NSE close on 30 Oct 2026. Previous close ₹2.93.

30 Oct: open ₹2.90, high ₹2.95, low ₹2.86

52-week range of traded prices to 30 Oct 2026
₹2.68Low, 12 Oct 2026₹5.50High, 9 Feb 2026
Market cap
₹52 Cr3,140th largest listed
P/E
13.14
P/B
Shares changed
Dividend yield
Nonein the last 12 months
ROE
4.4%
ROCE
4.1%
Debt to equity
0.19
Volume, NSE
1,11,79585.8% delivered

Ajooni Biotech's financial statements for the 9 years to Mar 2026, standalone: the listed company alone, without its subsidiaries, with the twelve months to Jun 2026 after them.

9 years at a glance

₹ crore, years to March.Ajooni Biotech annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
420.4Mar 18400.4Mar 19400.3Mar 20510.4Mar 21741.0Mar 22741.15,17,693Mar 23802.22.2Mar 241153.41.9Mar 251824.318Mar 26
Peak revenue ₹182 Cr, year to Mar 2026; lowest ₹40 Cr, year to Mar 2019

Operating and net margin, per cent

  • Operating margin
  • Net margin
4.2%0.7%2.2%1.4%2.7%3.2%4.2%3.7%2.8%3.2%3.4%0.9%1.0%0.9%0.7%1.4%1.5%2.7%2.9%2.4%Mar 18Mar 20Mar 22Mar 24Mar 26

Results for the year to Mar 2026

Standalone: the listed company alone, without its subsidiaries. ₹ crore.

From revenue to net profit

  1. Revenue182
  2. Materials and goods−148
  3. Employee costs−4.6
  4. Other expenses−24
  5. Operating profit6.3
  6. Depreciation−2.2
  7. Other income+2.4
  8. One-off items0.0
  9. Finance costs−0.7
  10. Profit before tax5.7
  11. Tax−1.4
  12. Net profit4.3

What the company owns

  • Plant, investments and other assets₹63 Cr
  • Inventory₹39 Cr
  • Receivables₹18 Cr
  • Cash and bank₹0 Cr

What pays for it: net worth and liabilities

  • Net worth₹91 Cr
  • Borrowings₹18 Cr
  • Owed to suppliers₹9 Cr
  • Other liabilities₹2 Cr

Profit and loss

Standalone, ₹ crore, years to March. The last column is the twelve months to Jun 2026, the latest four quarters added.Ajooni Biotech quarterly results

₹ croreMar 2018Mar 2019Mar 2020Mar 2021Filed 23 JunMar 2022Filed 9 MayMar 2023Mar 2024Mar 2025Mar 2026Filed 28 MayJun 2026Twelve monthsFiled 14 Aug
Revenue from operations42404051747480115182215
41393949717278111176207
Materials and goods bought3836354364667097148176
Employee costs1111122355
Other expenses3235546112426
Operating profit before depreciation1112332467
Operating margin2.2%1.4%2.7%3.2%4.2%3.7%2.8%3.2%3.4%3.4%
Materials, % of revenue88.9%91.8%87.2%84.3%86.5%88.3%87.8%84.6%81.1%82.2%
Employee costs, % of revenue2.1%1.8%2.8%2.2%2.0%2.4%2.2%2.4%2.5%2.3%
Other expenses, % of revenue6.8%5.0%7.3%10.2%7.4%5.7%7.2%9.8%13.0%12.1%
Depreciation and amortisation0001111123
Operating profit after depreciation1011221344
Other income0000002222
Finance costs0001101011
One-off items0000000000
Profit before tax0001123465
0000001111
Net profit0000112344
Other comprehensive income––0−202−10−1−1
Total comprehensive income––0−1131333
Net margin0.9%1.0%0.9%0.7%1.4%1.5%2.7%2.9%2.4%1.8%

Balance sheet

Standalone, ₹ crore, at 31 March.

₹ croreMar 2023Mar 2024Mar 2025Mar 2026Filed 28 May
41,66,933438891
Share capital17,52,274183434
Reserves24,14,658255457
5,17,6932218
15,20,9443527
1,85,268222
Total assets58,73,1444895120
24,06,022153346
34,67,122326274
Net debt4,86,7592−517
Borrowings are counted again inside the liabilities due within a year and after a year. No balance sheet is on record for the years to Mar 2018, Mar 2019, Mar 2020, Mar 2021 and Mar 2022, so its lines and the ratios worked from it are blank there.

Cash flow

Standalone, ₹ crore, years to March.

₹ croreMar 2021Filed 23 JunMar 2022Filed 9 MayMar 2023Mar 2024Mar 2025Mar 2026Filed 28 May
1.23.7−5.6−4.0−17.7−5.7
1.23.8−5.1−3.5−16.3−5.2
−0.40.7−8.0−7.3−21.7−13.1
Receivables−1.1−0.1−6.77.6−3.3−1.6
Inventories−2.1−0.5−1.1−8.4−8.6−15.5
Payables3.51.43.3−8.51.95.4
Other working capital−0.70.0−3.52.0−11.8−1.5
Tax paid0.0−0.2−0.4−0.5−0.90.0
Interest paid0.00.00.00.60.30.7
Capital spending3.52.12.90.01.018.0
Free cash flow−2.41.6−8.4−4.0−18.7−23.8
−3.4−1.9−15.87.6−17.1−15.8
2.4−2.021.7−3.624.815.1
Dividends paid0.00.00.00.00.00.0
Shares bought back0.00.00.00.00.00.0
Shares issued1.20.07.50.00.00.0
Net change in cash0.1−0.20.30.1−10.0−6.4
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the years to Mar 2018, Mar 2019 and Mar 2020.

Per share

Standalone, ₹ per share, years to March.

₹ per shareMar 2020Mar 2021Filed 23 JunMar 2022Filed 9 MayMar 2023Mar 2024Mar 2025Mar 2026Filed 28 May
₹0.07₹0.07₹0.21₹1.94₹0.25₹0.20₹0.25
As stated that year₹0.41₹0.37₹1.05₹1.94₹0.25₹0.20₹0.25
₹0.07₹0.07₹0.21₹1.94₹0.25₹0.20₹0.25
Book value per share–––₹4,75,602.74₹4.87₹5.11₹5.29
Shareholder yield–−3.9%0.0%−21.7%0.0%0.0%0.0%
Market cap at the year end (₹ crore)6.430.467.334.651.796.566.1
Every year is restated for later splits and bonuses, so they do not break the line. The figure the company stated that year is under each line it differs from.

Ratios

Standalone, years to March.Ajooni Biotech PE ratio and valuation

RatioMar 2018Mar 2019Mar 2020Mar 2021Filed 23 JunMar 2022Filed 9 MayMar 2023Mar 2024Mar 2025Mar 2026Filed 28 May
Revenue growth–−6.3%0.8%27.5%45.1%0.6%7.6%43.2%59.0%
Operating profit growth–−41.4%103.4%49.8%86.5%−10.0%−19.2%65.1%69.6%
Net profit growth–6.4%−15.5%7.5%181.2%7.2%92.2%56.0%28.2%
Earnings per share growth–––0.3%183.8%823.8%−87.1%−20.0%25.0%
–––––0.0%0.0%5.2%4.8%
––––––0.0 pts5.2 pts−0.3 pts
From the net margin––––––0.0 pts0.0 pts−1.0 pts
From asset turnover––––––0.0 pts6.7 pts0.2 pts
From borrowing––––––0.0 pts−1.5 pts0.4 pts
Return on capital employed–––––0.0%3.0%2.9%3.7%
Cash conversion–––310.8%351.2%−496.1%−182.9%−526.0%−132.7%
Interest cover1.82.32.31.83.63.72.47.85.6
Debt to equity–––––0.120.050.020.19
Receivable days–––––1,00,70,332595236
Inventory days–––––38,83,010809097
Payable days–––––56,13,65081322
Cash conversion cycle, days–––––83,39,692131129111
Working capital days–––––1,10,65,901134160126
Asset turnover–––––0.000.001.611.69
Assets per rupee of net worth–––––1.411.411.091.20
Sales per rupee of plant–––––0.007.7610.497.05
Capital spending to depreciation–––6.111.912.850.000.878.17
Plant being built, % of plant in use–––––4.2%9.0%2.7%0.0%
No balance sheet is on record for the years to Mar 2018, Mar 2019, Mar 2020, Mar 2021 and Mar 2022, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Standalone: the listed company alone, without its subsidiaries. Each window ends with the year to Mar 2026.

Return on assets, latest year
4.0%
Cash from operations against operating profit
−91.7%
Measure10 years5 years3 years
Revenue growth, yearly rate–29.0%34.8%
Profit growth, yearly rate–63.2%56.6%
Return on equity, average–2.5%3.3%
Return on capital employed, average–2.4%3.2%
Operating margin, average3.0%3.5%3.1%
Net margin, average1.6%2.2%2.7%
Asset turnover, average–0.831.10
Cash conversion cycle, days, average–20,85,016123
Interest cover, average3.54.65.3
Debt to equity, average–0.100.09

Where the cash came from and went

Standalone: the listed company alone, without its subsidiaries. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore5 years3 yearsLatest year
Cash from operations−29.3−27.4−5.7
Cash from investing−43.0−25.3−15.8
Cash from financing56.036.415.1
Capital spending24.019.018.0
Dividends paid0.00.00.0
Shares bought back0.00.00.0
Shares issued for cash7.50.00.0
Borrowings raised––16.2
Borrowings repaid3.50.70.4

Accounting checks

Standalone, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Piotroski score, out of 9Published threshold 3 points out of 9–––––––64
Altman Z-scorePublished threshold 1.81–––––0.979.8611.184.18
Beneish M-scorePublished threshold −1.78––––––−2.98−0.27−3.47
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets––––––0.0053.6523.98
Cash from operations to profit, 3 yearsPublished threshold 0.7 times–––––−0.29−1.35−4.10−2.78
Receivables growth less revenue growthOur threshold 0 percentage points––––––−107.55−18.03−49.04
Inventory growth less cost-of-goods growthOur threshold 0 percentage points––––––−107.0118.1712.03
Other current assets growth less revenue growthOur threshold 5 per cent of revenue––––––−3,47,420.501.400.52
Assets under construction, years of additionsOur threshold 2 years of additions–––––––0.170.00
Effective tax ratePublished threshold 17.16 per cent20.8613.4827.8426.0228.2228.6827.8722.1124.68
Tax charged less tax paid, % of profitOur threshold 10 percentage points––––17.440.299.761.9024.68
A threshold marked as ours has no published figure; it is the line we read the check against.

Credit ratings

An agency's view of the chance the company repays a borrowing on time, from AAA, the highest, down to D, in default.

DateAgencyBorrowing ratedRatingOutlookAmount, ₹ Cr
4 May 2026CRISIL Ratings LimitedBank FacilitiesCrisil BB+Review, OtherStable4
The latest rating on each borrowing. The agency's name opens its reasoning for the rating.